<DOC>
	<DOCNO>NCT00836082</DOCNO>
	<brief_summary>To determine PF-04457845 dos 0.5mg , 1mg , 4mg , 8 mg give daily 14 day safe well tolerate healthy volunteer . To determine effect food PF-04457845 pharmacokinetics safety follow administration single dose 4mg 8mg .</brief_summary>
	<brief_title>A Multiple Dose Trial Evaluating Safety , Tolerability , Pharmacokinetics Pharmacodynamics PF-04457845 Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Chronic Pain</mesh_term>
	<mesh_term>Acute Pain</mesh_term>
	<criteria>Healthy male and/or female subject ( non childbearing potential ) age 18 55 year , inclusive ( Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12lead ECG clinical laboratory test ) . Body Mass Index ( BMI ) approximately 18 30 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . Evidence personally sign date informed consent document indicate subject ( legally acceptable representative ) inform pertinent aspect study . Subjects willing able comply schedule visit , treatment plan , laboratory test , study procedure . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular ( include hyperlipidemia ) , pancreatic , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . History febrile illness within 5 day prior first dose . Any condition possibly affect drug absorption ( eg , gastrectomy ) . A positive urine drug screen . History regular alcohol consumption exceed 14 drinks/week female 21 drinks/week men ( 1 drink = 5 ounce ( 150 mL ) wine 12 ounce ( 360 mL ) beer 1.5 ounce ( 45 mL ) hard liquor ) within 6 month screen . Treatment investigational drug within 30 day ( determined local requirement , whichever long ) 5 halflives precede first dose study medication . 12lead ECG demonstrate QTc &gt; 450 msec screening . If QTc exceed 450msec , ECG repeat two time average three QTc value use determine subject 's eligibility . Females childbearing potential . Use prescription nonprescription drug , dietary supplement within 7 day 5 halflives ( whichever longer ) prior first dose study medication . Herbal supplement hormonal replacement therapy must discontinue 28 day prior first dose study medication . As exception , ibuprofen may use dos 1800 mg/day food . Limited use nonprescription medication believe affect subject safety overall result study may permit case bycase basis follow approval sponsor . Unwillingness refrain consumption grapefruit grapefruit/pomelo containing product within 7 day prior first dose study medication completion followup visit . Blood donation approximately 1 pint ( 500 mL ) within 56 day prior dose . Unwilling unable comply Lifestyle guideline describe protocol . Subject Investigator subInvestigator . research assistant , pharmacist , study coordinator , staff , relative study personnel directly involve conduct study . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment investigator , would make subject inappropriate entry study . The use marijuana ( illicit drug ) within 30 day randomization .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Healthy volunteer</keyword>
</DOC>